Skip to main content
SpringerLink
Log in

Safety and Tolerability of Treatments for Allergic Rhinitis in Children

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Allergic rhinitis is a common condition in adults and children and can have a large impact on patients’ health and quality of life. The aim of current allergic rhinitis therapies is to treat the subjective symptoms and to improve objective measures of the disease. Of the available treatment options for paediatric allergic rhinitis, the newer oral antihistamines and intranasal corticosteroids are first-line treatments.

First-generation antihistamines are associated with unwanted adverse effects such as cardiotoxicity, sedation and impairment of psychomotor function. Despite results from studies using first-generation antihistamines demonstrating impairment of cognitive and academic function in children, many of these agents are still commonly given to patients. The newer antihistamines, developed with the aim of being more specific for the histamine H1 receptor and of overcoming these adverse effects, are the medication of choice in patients with mild intermittent allergic rhinitis. For children <12 years of age, three newer oral antihistamines are currently available: cetirizine, loratadine and fexofenadine. A lack of adverse effects with these antihistamines has been demonstrated in children using EEG and psychomotor performance tests, and in clinical studies. However, issues of receptor selectivity and the potential for CNS adverse effects still remain, and further studies are warranted.

Intranasal corticosteroids are the most effective anti-inflammatory agents used for the treatment of paediatric allergic rhinitis; however, the safety of these compounds remains controversial. The safety implications associated with corticosteroids are long-term, dose-related systemic effects, such as suppression of adrenocortical function, growth and bone metabolism, and the extent of these effects is influenced by a number of factors including corticosteroid type, pharmacokinetic profile, mode of delivery and delivery device. Topical corticosteroids were introduced to reduce the systemic effects seen with the long-term use of oral agents. The intranasal corticosteroids currently available for the treatment of paediatric allergic rhinitis — beclometasone, budesonide, flunisolide, fluticasone propionate, mometasone and triamcinolone — have short half-lives and rapid first-pass hepatic metabolism; however, their pharmacokinetics vary in terms of systemic absorption, potency, binding affinity, lipophilicity, volume of distribution, and half-life. A number of studies — utilising hypothalamic-pituitary-adrenal axis function tests such as plasma cortisol levels, 24-hour urinary-free cortisol tests; stimulation tests with corticotropin (adrenocorticotropic hormone), lypressin, and corticotropin-releasing hormone; and growth assessment studies using knemometry and stadiometry — have indicated that these intranasal corticosteroids are well-tolerated in paediatric patients and do not significantly affect growth.

The wealth of clinical data and the recommendations from evidence-based guidelines suggest that both antihistamines and intranasal corticosteroids have good safety profiles in children. Nevertheless, growth should be regularly monitored in children receiving intranasal corticosteroids. Other treatments such as immunotherapy, local chromones and decongestants can also be beneficial in managing paediatric allergic rhinitis, and therapies should be considered on an individual basis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 1998; 351: 1225–32

    Google Scholar 

  2. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 Nov; 108(5 Suppl.): S147–334

    Article  PubMed  CAS  Google Scholar 

  3. Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physician diagnosed allergic rhinitis in childhood. Pediatrics 1994; 94: 895–901

    PubMed  CAS  Google Scholar 

  4. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child. Bio-drugs 2001; 15: 453–63

    CAS  Google Scholar 

  5. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518

    Article  PubMed  CAS  Google Scholar 

  6. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001; 108Suppl. 1: S45–53

    Article  PubMed  CAS  Google Scholar 

  7. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999; 20: 209–13

    Article  PubMed  CAS  Google Scholar 

  8. Baena-Cagnani C. Allergic rhinitis and asthma in children: disease management and outcomes. Curr Allergy Asthma Rep 2001; 1: 515–22

    Article  PubMed  CAS  Google Scholar 

  9. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116–34

    Article  PubMed  Google Scholar 

  10. Jumbelic MI, Hanzlick R, Cohle S. Alkylamine antihistamine toxicity and review of pediatric registry of the National Association of Medical Examiners. Am J Forensic Med Pathol 1997; 18: 65–9

    Article  PubMed  CAS  Google Scholar 

  11. Garza MB, Osterhoudt KC, Rutstein R. Central anticholinergic syndrome from orphenadrine in a 3-year-old. Pediatr Emerg Care 2000; 16: 97–6

    Article  PubMed  CAS  Google Scholar 

  12. Goetz CM, Lopez G, Dean BS, et al. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med 1990; 8: 321–2

    Article  PubMed  CAS  Google Scholar 

  13. Le Blaye I, Donatini B, Hall M, et al. Acute ketotifen overdosage: a review of present clinical experience. Drug Saf 1992; 7(5): 387–92

    Article  PubMed  Google Scholar 

  14. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999; 29Suppl. 3: 133–42

    Article  PubMed  CAS  Google Scholar 

  15. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 65Suppl. 56: 21–7

    Google Scholar 

  16. Brannan JD, Anderson SD, Gomes K, et al. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420–5

    PubMed  CAS  Google Scholar 

  17. The ETAC Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial: first results of ETAC Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998; 9 (3): 116–24

  18. Graft DF, Bernstein DI, Goldsobel A, et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 22–6

    Article  PubMed  CAS  Google Scholar 

  19. Wahn U, Hedlin G, Ruuth E, et al. Assessment of safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis [abstract]. Allergy 2002; 57Suppl. 73: 673

    Google Scholar 

  20. Tinkelman DJ, Kemp J, Mitchell DQ, et al. Treatment of seasonal allergic rhinitis in children with cetirizine and chlorpheniramine: a multi-center study. Pediatr Asthma Allergy Immunol 1996; 10: 9–17

    Article  Google Scholar 

  21. Baelde Y, Dupont P. Cetirizine in children with chronic allergic rhinitis. Drug Invest 1992; 4: 466–72

    Article  Google Scholar 

  22. Allegra L, Paupe J, Wieseman HG, et al. Cetirizine for seasonal allergic rhinitis in children aged 2-6 years: a double-blind comparison with placebo. Pediatr Allergy Immunol 1993; 4(3): 157–61

    Article  PubMed  CAS  Google Scholar 

  23. Simons FER. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group: early treatment of the atopic child. J Allergy Clin Immunol 1999; 104: 433–40

    Article  PubMed  CAS  Google Scholar 

  24. Lutsky BN, Klose P, Melon M, et al. A comparative study of the efficacy and safety of loratadine and terfenadine suspension in the treatment of 3 to 6 year old children with SAR. Clin Ther 1993; 15: 855–65

    PubMed  CAS  Google Scholar 

  25. Delgado LF, Pferferman A, Sole D, et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998; 80: 333–7

    Article  PubMed  CAS  Google Scholar 

  26. Ellis J, Seidenberg M. Desloratadine is a potent antagonist at muscarinic acetylcholine receptors, but fexofenadine is not [abstract]. Allergy 2001; 56Suppl. 68: 202, 642

    Google Scholar 

  27. Igawa A, Cheg CP, Little W. Desloratadine, but no fexofenadine, increases the heart rate in dogs before and after heart failure. Allergy 2001; 56Suppl. 68: 203–4

    Google Scholar 

  28. Tobin JR, Doyle TP, Ackerman AD, et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737–40

    Article  PubMed  CAS  Google Scholar 

  29. Hoppu K, Tikanoja T, Tapanainen P, et al. Accidental astemizole overdose in young children. Lancet 1991; 338: 538–40

    Article  PubMed  CAS  Google Scholar 

  30. Wiley II JF, Gelber ML, Henretig FM, et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120: 799–802

    Article  PubMed  Google Scholar 

  31. Simons FER, Kesselman MS, Giddens NG, et al. Astemizole-induced torsade de pointes [letter]. Lancet 1988; II: 624

    Article  Google Scholar 

  32. Pratt C, Brown A, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999; 29(3): 212–6

    Article  PubMed  CAS  Google Scholar 

  33. Taglialatela M, Castaldo P, Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999; 29Suppl. 3: 182–9

    Article  PubMed  CAS  Google Scholar 

  34. Zhou A, Vorperian VR, Gong Q, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999; 10: 836–43

    Article  PubMed  CAS  Google Scholar 

  35. Crumb WJ. Loratadine blockade of K+ channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 2000; 292: 261–4

    PubMed  CAS  Google Scholar 

  36. Winder J, Noonan MJ. A randomized, placebo-controlled study to evaluate the cardiographic effects of cetirizine in children aged 6 to 11 [abstract]. J Allergy Clin Immunol 1996; 97: 342

    Article  Google Scholar 

  37. Harrison JE, Danzig MR, Lorber RR. The electrocardiographic effects of loratadine syrup in pediatric patients [abstract]. J Allergy Clin Immunol 1996; 97: 437

    Article  Google Scholar 

  38. Simons FER. H1-antihistamines in children. In: Simons FER, editor. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York: Marcel Dekker Inc, 2002: 437–64

    Google Scholar 

  39. Passalacqua G, Scordamaglia A, Ruffoni S, et al. Sedation from H1 antagonists: evaluation methods and experimental results. Allergol Immunopathol (Madr) 1993; 21: 79–83

    CAS  Google Scholar 

  40. Cookson J, Taylor D, Katona C. Use of drugs in psychiatry. 5th ed. London: Gaskell, 2002: 408

    Google Scholar 

  41. Yasahara A, Ochi A, Harada Y, et al. Infantile spasms associated with a histamine H1-antagonist. Neuropediatrics 1998; 29: 320–1

    Article  Google Scholar 

  42. Yokoyama H, Iinuma K, Yanai K, et al. Proconvulsant effect of ketotifen, a histamine H1-antagonist, confirmed by the use of d-chloropheniramine with monitoring electroencephalography. Methods Find Exp Clin Pharmacol 1993; 15: 183–8

    PubMed  CAS  Google Scholar 

  43. Vuurman E, van Veggel L, Uiterwijk M, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6

    PubMed  CAS  Google Scholar 

  44. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996 Jul-Aug; 17(4): 185–9

    Article  PubMed  CAS  Google Scholar 

  45. Falliers CJ, Brandon ML, Buchman E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991 Mar; 66(3): 257–62

    PubMed  CAS  Google Scholar 

  46. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32: 133–9

    Article  PubMed  CAS  Google Scholar 

  47. Ridout F, Meadows R, Johnsen S, et al. Effects of desloratadine 5, 10 and 20mg, and promethazine 25mg on cognitive and psychomotor performance [abstract]. Ann Allergy Asthma Immunol 2003; 90(1): 124, P35

    Google Scholar 

  48. Feldman W, Shanon A, Leiken L, et al. Central nervous system side-effects of antihistamines in schoolchildren. Rhinology 1992; 13: 13–9

    CAS  Google Scholar 

  49. Simons FER, Reggin JD, Roberts JR, et al. Benefit/risk ratio of the antihistamines (h1-receptor antagonists) terfenadine and chlorpheniramime in children. J Pediatr 1994; 124: 979–83

    Article  PubMed  CAS  Google Scholar 

  50. Simons FER, Fraser TG, Reggin JD, et al. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol 1996; 7: 22–7

    Article  PubMed  CAS  Google Scholar 

  51. Stevenson J, Cornah D, Evrard P, et al. and The ETAC Study Group. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behaviour, cognitive and psychomotor development of very young children with atopic dermatitis. Pediatr Res 2002; 52(2): 251–7

    Article  PubMed  CAS  Google Scholar 

  52. Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000; 106: S179–90

    Article  PubMed  CAS  Google Scholar 

  53. Sizonenko PC. Effects of inhaled or nasal glucocorticosteroids on adrenal function and growth. J Pediatr Endocrinol Metab 2002; 15: 5–26

    Article  PubMed  CAS  Google Scholar 

  54. Kokron CM, Castro AS, Sole D, et al. Lysine-vasopressin in the evaluation of the hypothalamic-pituitary-adrenal axis in children with allergic rhinitis treated with intranasal beclomethasone dipropionate or oral prednisone. J Investig Allergol Clin Immunol 1997; 7: 51–6

    PubMed  CAS  Google Scholar 

  55. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993; 92: 594–9

    PubMed  CAS  Google Scholar 

  56. Agertoft L, Wolthers OD, Fuglsang G, et al. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993; 4: 152–6

    Article  PubMed  CAS  Google Scholar 

  57. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray [abstract]. Pediatrics 2000; 105: E22

    Article  PubMed  CAS  Google Scholar 

  58. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate [abstract]. Pediatrics 2000; 105: E23

    Article  PubMed  CAS  Google Scholar 

  59. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children: Fluticasone Propionate Collaborative Pediatric Working Group. J Pediatr 1994; 125: 628–34

  60. Skoner D, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 56–62

    Article  PubMed  CAS  Google Scholar 

  61. Brannan MD, Herron JM, Affrime MB, et al. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19: 1330–9

    Article  PubMed  CAS  Google Scholar 

  62. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 107–14

    Article  PubMed  CAS  Google Scholar 

  63. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocorticol function in children with allergic rhinitis. J Allergy Clin Immunol 1998; 101: 157–62

    Article  PubMed  CAS  Google Scholar 

  64. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993; 82: 635–40

    PubMed  CAS  Google Scholar 

  65. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 1994; 49: 96–9

    Article  PubMed  CAS  Google Scholar 

  66. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999; 104(5): 948–52

    Article  PubMed  CAS  Google Scholar 

  67. Mansfield LE, Mendoza CP. Medium and long-term growth in children receiving intranasal beclomethasone dipropionate: a clinical experience. South Med J 2002; 95: 334–40

    PubMed  Google Scholar 

  68. Allen DB, Meltzer EO, Lemanske Jr RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23: 407–13

    PubMed  CAS  Google Scholar 

  69. Wilson A, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998 Oct; 102: 598–604

    Article  PubMed  CAS  Google Scholar 

  70. Martinati LC, Sette L, Chiocca E, et al. Effect of beclomethasone dipropionate nasal aerosol on serum markers of bone metabolism in children with seasonal allergic rhinitis. Clin Exp Allergy 1993; 23: 986–91

    Article  PubMed  CAS  Google Scholar 

  71. Toogood JH, Jennings B, Crepea SB, et al. Efficacy and safety of concurrent use of intranasal fluinsolide and oral beclomethasone aerosols in the treatment of asthmatics with rhinitis. Clin Allergy 1982; 12: 95–105

    Article  PubMed  CAS  Google Scholar 

  72. Herman D, Garay R, Le Gal M, et al. A randomized, double-blind, placebo controlled study of azelastine nasal spray in children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 1997; 39: 1–8

    Article  PubMed  CAS  Google Scholar 

  73. Azelastine (Astelin®) prescribing information [online]. Available from URL: http://www.astelin.com/productinfo/pi.html#adverse1 [Accessed 2003 Jan]

  74. Schenkel EJ. Paediatric issues relating to the pharmacotherapy of allergic rhinitis. Expert Opin Pharmacother 2000; 1: 1289–306

    Article  PubMed  CAS  Google Scholar 

  75. Bousquet J, Lockey RF, Malling H-J. WHO position paper: allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53Suppl. 44: 1–42

    Google Scholar 

  76. Passalacqua G, Canonica GW. Alternative routes of immunotherapy: a review. J Invest Allergol Clin Immunol 1996; 36: 81–7

    Google Scholar 

  77. Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in mono sensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy 2001; 31: 1295–302

    Article  PubMed  Google Scholar 

  78. Pajno G, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001; 31: 1392–7

    Article  PubMed  CAS  Google Scholar 

  79. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251–6

    Article  PubMed  Google Scholar 

  80. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32: 1020–8

    Article  PubMed  CAS  Google Scholar 

  81. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 344–9

    Article  PubMed  CAS  Google Scholar 

  82. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949–55

    Article  PubMed  CAS  Google Scholar 

  83. Wilson AM, Orr LC, Coutie WJ, et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhintis. Clin Exp Allergy 2002; 32: 126–32

    Article  PubMed  CAS  Google Scholar 

  84. Casale TB. Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis. J Allergy Clin Immunol 2001 Aug; 108(2 Suppl.): S84–8

    Article  PubMed  CAS  Google Scholar 

  85. Naclerio R, Rosenwasser L, Ohkubo K. Allergic rhinitis: current and future treatments. Clin Exp Allergy Rev 2002; 2: 137–47

    Article  Google Scholar 

  86. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999 May 10; 159(9): 941–55

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author has received educational grants from the Catholic University of Cordoba, Cordoba, Argentina, and honoraria as a consultant/speaker bureau member for Aventis, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Schering Plough. The author has also had research support from Aventis, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Schering Plough.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Catholic University of Cordoba, Santa Rosa 381, Cordoba, X5000ESG, Argentina

    Carlos E. Baena-Cagnani

Authors
  1. Carlos E. Baena-Cagnani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baena-Cagnani, C.E. Safety and Tolerability of Treatments for Allergic Rhinitis in Children. Drug-Safety 27, 883–898 (2004). https://doi.org/10.2165/00002018-200427120-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427120-00005

Keywords

Search

Navigation